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Glycogen synthase kinase 3 (GSK3) β and α are serine/threonine kinases involved
in many biological processes. A primary mechanism of GSK3 activity regulation is
phosphorylation of N-terminal serine (S) residues (S9 in GSK3β, S21 in GSK3α).
Phosphorylation is inhibitory to GSK3 kinase activity because the phosphorylated
N-terminus acts as a competitive inhibitor for primed substrates. Despite widespread
interest in GSK3 across most fields of biology, the research community does not
have reagents that specifically react with nonphosphoS9/21 GSK3β/α (the so-called
“active” form). Here, we describe two novel monoclonal antibodies that specifically
react with nonphosphoS9/21 GSK3β/α in multiple species (human, mouse, and rat).
One of the antibodies is specific for nonphospho-S9 GSK3β (clone 12B2) and one
for nonphospho-S9/21 GSK3β/α (clone 15C2). These reagents were validated for
specificity and reactivity in several biochemical and immunochemical assays, and they
show linear detection of nonphosphoS GSK3. Finally, these reagents provide significant
advantages in studying GSK3β regulation. We used both antibodies to study the
regulation of S9 phosphorylation by Akt and protein phosphatases. We used 12B2 (due
to its specificity for GSK3β) and to demonstrate that protein phosphatase inhibition
reduces nonphospho-S9 GSK3β levels and lowers kinase activity within cells. The
ability to use the same reagent across biochemical, immunohistological and kinase
activity assays provides a powerful approach for studying serine-dependent regulation
of GSK3β/α.
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INTRODUCTION
Glycogen synthase kinase (GSK) was described in the 80’s for its role in regulating glycogen
synthase (Embi et al., 1980; Rylatt et al., 1980). GSK3 is a highly conserved serine (S)/threonine
(T) kinase and two genes encode the α and β paralogs. The primary consensus sequence of
GSK3β substrates is S/T-X-X-X-pS/pT, where phosphorylation of the target S/T is facilitated by
a “priming” phosphate group on a S or T four amino acids downstream (Forde and Dale, 2007;
Medina and Wandosell, 2011). The primed residue binds the primed substrate pocket bringing
the target S/T residue into the kinase domain (Beurel et al., 2015). A number of GSK3β substrates
such as glycogen synthase, β-catenin and tau are phosphorylated by GSK3β after being primed by
other kinases (Zhang et al., 1993; Hagen and Vidal-Puig, 2002; Li et al., 2006), but not all GSK3β
substrates require priming (Wang et al., 1994b).
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Over 80 proposed GSK3 targets exist (most of which are
not exclusive GSK3 substrates) and this kinase plays a role in
numerous biological processes such as cell proliferation, cell
migration, cell polarization, transcription, glucose regulation, the
immune system, and inflammation (Frame and Cohen, 2001;
Kim and Kimmel, 2006; Kockeritz et al., 2006; Sutherland,
2011; Beurel et al., 2015). Canonical Wnt signaling, where it
phosphorylates β-catenin to signal the degradation of β-catenin,
is a well-studied GSK3β pathway (Aberle et al., 1997; Chen et al.,
2000; McManus et al., 2005). GSK3β also is involved in apoptosis,
cancer biology, and several neurodegenerative diseases (Hetman
et al., 2000; Hernandez and Avila, 2008; Cadigan and Peifer,
2009; Golpich et al., 2015; Li et al., 2015; O’Leary and Nolan,
2015). With such diverse functions, it is not surprising that GSK3
activity is tightly regulated.
In general, phosphorylation at S9 in GSK3β or S21
in GSK3α by other kinases and/or autophosphorylation is
the prominent regulatory mechanism, but several additional
regulatory mechanisms exist (Beurel et al., 2015). S9/S21
phosphorylation leads to inactivation because the N-terminus
of GSK3 competitively blocks substrate docking in the primed
substrate pocket (Frame et al., 2001) acting as a dominant
negative regulator of GSK3 activity, especially against substrates
requiring priming. In situ, GSK3 is regulated, at least in part,
by phosphorylation at S9 from Akt leading to reduced activity
(Gold et al., 2000; Varea et al., 2010; Majewska and Szeliga, 2016)
and protein phosphatases that dephosphorylate S9 leading to
increased activity under several biological contexts (Sutherland
et al., 1993; Leung-Hagesteijn et al., 2001; Morfini et al.,
2004; Lee et al., 2005; Szatmari et al., 2005; Bertrand et al.,
2012). However, the lack of reagents that specifically detect
nonphospho-S9 (npS9) GSK3 has limited our ability to directly
study dephosphorylation of this N-terminal serine. The activity
of GSK3 is augmented by the phosphorylation of tyrosine 216 in
GSK3β or tyrosine 279 in GSK3α, (Hughes et al., 1993; Frame
and Cohen, 2001), but tyrosine phosphorylation appears to be
mostly derived from chaperone-dependent autophosphorylation
during (or shortly after) translation and stabilizes the enzymes
(Wang et al., 1994a; Cole et al., 2004; Lochhead et al.,
2006).
Reagents for specifically assessing changes in the pool
of “active” GSK3β/α (i.e., npS9/21) do not exist. Currently,
researchers rely on the use of phospho-S9 GSK3β or phospho-
S21 GSK3α antibodies for detecting “inactive” enzymes. These
approaches only indirectly measure active GSK3 by comparing
changes in the ratio of phospho-Ser GSK3 to total GSK3.
Moreover, kinase activity assays are available, but the required
specificity for GSK3β is not currently possible in lysates. Instead,
GSK3β activity assays are performed by immunoprecipitating
GSK3β and then measuring activity with GSK3β substrate
peptides or proteins (Welsh et al., 1997; Bijur and Jope, 2001;
Bowley et al., 2005). Reagents that directly detect the amount of
npS9 GSK3β and can be used in GSK3β kinase activity assays
would provide obvious advantages to biochemical analyses and
allow localization within cells and tissues. Thus, we set out to
generate novel monoclonal antibodies against npS9 in GSK3β
because of the lack of such reagents, involvement of GSK3β in
several processes and the broad interest in GSK3β across many
fields.
MATERIALS AND METHODS
Synthetic GSK3 Peptides
The GSK3β immunization peptides were synthesized and
Keyhole Limpet hemocyanin (KLH) was conjugated to the
N-termini by GenScript (Piscataway, NJ, USA). The following
peptides were generated using variations within the first
14 amino acids of human GSK3β (Uniprot ID: P49841),
(1) N-term KLH npS9 GSK3β peptide: 1-14 GSK3β (KLH-
1MSGRPRTTSFAESC14), (2) arginine enantiomer npS9 GSK3β
peptide (KLH-1MSG[d-R]PRTTSFAESC14) and (3) tandem
npS9 GSK3β peptide (KLH-4RPRTTSFAES13/4RPRTTSFAES13).
These KLH-peptide reagents were >90% pure and stocks
at 2 mg/ml were diluted in H2O and stored at −20◦C until
used for immunizations as described below. The following
four peptides GSK3β and α screening peptides were used for
screening during monoclonal antibody production, (1) npS9
GSK3β (1MSGRPRTTSFAESCKPVQQPSAFGS25), (2) pS9
GSK3β (1MSGRPRTT[pS]FAESCKPVQQPSAFGS25), (3) npS21
GSK3α (10GPGGSGRARTSSFAEPGGG28) and (4) pS21 GSK3α
(10GPGGSGRARTS[pS]FAEPGGG28). These peptides were
>90% pure and stocks at 1 mg/ml diluted in H2O were stored at
−20◦C until used in assays as indicated below.
Animal and Human Subjects
Three-month-old BALB/c female mice were used for
immunizations. A male C57BL/6J wild-type mouse and male
Fisher 344 rat were perfused with 0.9% saline containing heparin
for fresh tissue samples. A male Fisher 344 rat was perfused for
fixed tissue as described Grabinski et al. (2015). Timed-pregnant
female Sprague Dawley rats were used to obtain E18 fetal
cortical cells for primary neuron cultures as described Grabinski
et al. (2015). All studies involving animals were conducted in
compliance with federal, state and institutional guidelines and
approved by the Michigan State University Institutional Animal
Care and Use Committee.
Fresh frozen tissue from the frontal cortex of an aged, non-
demented case (sex: male, age: 75 years, post-mortem interval:
2.5 h) was used for biochemical analyses, and fixed tissue from
an aged non-demented case was used (sex: male, age: 80 years,
post-mortem interval: 3.25 h) for the immunohistochemical
analysis. The Michigan State University Institutional Review
Board approved all post-mortem human tissue studies for human
subject’s exemption. All of the samples were de-identified and
obtained through the Alzheimer’s Disease Research Center at
Banner Sun Health Research Institute (Beach et al., 2015).
Monoclonal Antibody Production
Animals received injections of the N-terminal peptide,
enantiomer peptide, tandem repeat peptide, or a mixture of
all three peptides (200 µg peptide) every 3 weeks and serum was
collected 3 days after the indicated immunizations to determine
antibody titer. Once serum titers showed above-background
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signal at ≥1:51,200 dilution, the animal was boosted again and
3 days later used for the fusion procedure. Hybridoma fusion
techniques similar to those described previously were used to
create monoclonal antibodies (Binder et al., 1985). Cultures were
screened for reactivity against npS9 GSK3β, pS9 GSK3β, pS9
GSK3β and pS21 GSK3β screening peptides by indirect ELISAs
7–10 days after plating. Cultures that were positive (i.e., typically
absorbance >1.0) were expanded, screened again and then
plated into 96-well (∼1 cell/well for first clone plating). Clones
were screened again, and the strongest wells were expanded in
medium consisting of RPMI-1640 supplemented with 1x HT
(11067-030, Thermo, Waltham, MA, USA), 10% Fetal bovine
serum, 5% L-Glutamine, 1% sodium pyruvate, and 1% penicillin-
streptomycin. Cells were subcloned following this process at
least three times and we require >95% of all wells are positive
in ELISAs. The third subclones were subjected to freeze/thaw
cycles (Hybridoma Freezing Medium: RPMI-1640, 10% FBS, 5%
L-Glutamine, 1% sodium pyruvate, 1% penicillin-streptomycin
and 5% DMSO) for a total of three times to establish stability
upon liquid nitrogen freezing and retrieval. Antibody isotypes
were determined using the IsoStrip Mouse Monoclonal Antibody
Isotyping Kit (11493027001, Roche) and mycoplasma testing was
performed using the Mycoplasma PCR ELISA kit (11663925910,
Roche). Once the clones were verified as clean, stable and positive
the antibodies were purified.
Each antibody was produced using CELLine 350 bioreactors
(Integra Biosciences, Hudson, NH, USA) according to the
manufacturer’s instructions. Culture supernatants were dialyzed
overnight in 1.5 M glycine, 3 M NaCl buffer, pH 8.9 (Protein A
buffer) using dialysis tubing (PI68100, Thermo). Dialyzed culture
supernatant was centrifuged at 12,000× g for 20 min and filtered
(5 µm pore filter) and purified using rProtein A Sepharose Fast
Flow resin (17-1279-01, GE Healthcare, Pittsburgh, PA, USA).
The antibodies were eluted using 0.1 M citric acid starting at pH
6, followed by pH 5, pH 4, and pH 3 (10 ml each). Fractions were
collected (5 ml), run on 4–20% Tris-HCl Criterion gels (567–
1093, BioRad, Hercules, CA, USA) and stained by Coomassie.
Fractions containing IgGs were pooled and concentrated in an
Amicon Ultra Centrifugal Unit (UFC90-30-24, Thermo) and
dialyzed overnight in antibody storage buffer (10 mM HEPES,
500 mM NaCl, 50% Glycerol). Concentrations were measured
using A280 (extinction coefficient of 13.7) and antibodies were
adjusted to 1 mg/ml, aliquoted and stored at−80◦C.
Indirect ELISAs
Indirect ELISAs were performed to determine the binding affinity
and specificity of each of the antibodies for non phospho and
phospho GSK3β and GSK3α peptides as described Kanaan et al.
(2011). For the antibody titer ELISAs, 50 µl of the GSK3
screening peptides (without KLH) were diluted to 2 ng/µl in
a borate saline solution (100 mM boric acid, 25 mM sodium
tetraborate decahydrate, 75 mM NaCl, 250 µM thimerosal)
and wells (Corning, #3590) were coated for 1 h. Between all
steps, wells were washed with ELISA wash solution (100 mM
boric acid, 25 mM sodium tetraborate decahydrate, 75 mM
NaCl, 250 µM thimerosal, 0.4% bovine serum albumin and
0.1% tween-20; 200 µl/well). Wells were blocked with 200 µl
5% non-fat dry milk made in ELISA wash solution (blocking
buffer) for 1 h. The purified GSK3 antibodies were serially
diluted in blocking buffer at a range from 1:400 (2500 ng/ml or
16.7 nM) to 1:819,200 (1.22 ng/ml or 6.7 pM) and incubated for
2 h. Goat anti-mouse HRP conjugated antibody (115-035-003,
Jackson ImmunoResearch, West Grove, PA, USA) was added to
each well at a dilution of 1:5,000 for 1 h. Reactivity was detected
by adding 3,3′,5,5′ tetramethylbenzidine substrate (T0440, Sigma
Aldrich, St. Louis, MO, USA) to each well and incubated for
approximately 8 min. Reactions were quenched with 50 µl 3.6%
H2SO4 and then the absorbance at 450 nm. Blank wells were
used to obtain background absorbance, which was removed from
sample signals. For antibody specificity ELISAs, the assays were
run as described above with the exception that the plates were
coated with a wide range of either npS9 GSK3β, pS GSK3β,
npS21 GSK3α, or pS21 GSK3α peptides (0 – 6.4 µg/well). The
peptides were detected using 12B2 (2 nM) or 15C2 (1 nM)
primary antibodies and signals were detected and analyzed as
above. Finally, we confirmed the presence of phosphorylation at
S9 in the pS9 GSK3β peptide (well coated with 50 µl at 2 ng/µl)
using the phosphoS9 GSK3β primary antibody (1:1,000; 9323,
Cell Signaling).
Cell Culture
Primary neurons from E18 rat cortex were cultured for 8 days as
described previously (Grabinski et al., 2015). Human embryonic
kidney (HEK) 293T cells (CRL-3216, ATCC) were grown
in DMEM (11995-065, Thermo) supplemented with 5% FBS
and 1% penicillin/streptomycin (15140-122, Thermo). Human
neuroblastoma SH-SY5Y cells (CRL-2266, ATCC) were grown in
Ham’s F-12 medium (11765-054, Thermo) mixed with Minimum
Essential Medium (11095-080, Thermo) at a ratio of 1:1 and
supplemented with 5% FBS and 1% penicillin/streptomycin.
Human glioblastoma U373 cells and mouse neuroblastoma
Neuro-2A cells were grown in DMEM/Ham’s F12 (10-090-
CV, Corning) supplemented with 10% FBS, 2mM L-glutamine
(25030-081, Thermo), 1% MEM Non-Essential Amino Acids
(11140-050, Thermo), and 1 mM sodium pyruvate (25000CI,
Corning). Cells were collected and processed for the specific
assays as outlined below.
siRNA Knockdown
HEK293T cells were plated in a 24-well plate at a density of 60,000
cells/well in 400 µl growth medium without antibiotics (DMEM
(11995-065, Thermo) supplemented with 5% FBS) 1 day prior
to transfection. HEK293T cells were transfected with either the
human GSK3β Stealth primer set (1299001-VHS40279, Thermo),
the human GSK3α Stealth primer set (1299001-HSS104518,
Thermo), the human GAPDH Stealth control (12935140,
Thermo), or the medium GC siRNA negative control (12935300,
Thermo) constructs according to manufacturer’s protocol. The
GAPDH siRNA controls for expression of a functional siRNA
against an unrelated target, and the medium GC siRNA is an
additional control for non-specific effects. The siRNA constructs
were diluted to 100 pM for GSK3α, 100 pM for GSK3β, 40 nM for
GAPDH or 10 nM for medium GC in 50 µl OPTI-MEM (31985-
070, Thermo). Lipofectamine 2000 (11668-027, Thermo) was
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mixed at a ratio of 1–50 µl OPTI-MEM and incubated at room
temperature for 15 min. Then, the siRNAs and Lipofectamine
2000 were combined and incubated at room temperature for
15 min. After the incubation, the reagents were added to the cells
(100 µl/well) and incubated for 48 h before collecting the cells
for Western blotting and immunocytofluorescence as described
below.
12B2 and 15C2 Antibody
Immunoprecipitations
Immunoprecipitations were performed by conjugating either
12B2, 15C2 or a non-immune mouse IgG to NHS Magnetic
Sepharose beads according to the manufacturer’s instructions
(28944009, GE Healthcare). Magnetic beads were prepared by
briefly equilibrating 25 µl of the bead slurry into ice cold 1 mM
HCl, then immediately removing equilibration buffer and adding
200 µl of the antibody at 25 ng/µl (5 µg total antibody diluted
in phosphate buffered saline: 137 mM, NaCl, 2.68 mM KCl,
10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4). The antibodies
were bound to the beads during a 40 min incubation at room
temperature with end over end mixing. Residual NHS active
groups were blocked following a series of washes and incubations
with two separate reagents. Beads were washed with 500 µl
blocking buffer A (50 mM tris-HCl, 1M NaCl, pH 8.0), followed
by washing with 500 µl blocking buffer B (50 mM glycine-HCl,
1M NaCl, pH 3.0), followed by incubation in 500 µl blocking
buffer A for 15 min with end over end mixing. Another series
of washes occurred starting with blocking buffer B, followed by
blocking buffer A, and then blocking buffer B. After removing the
final blocking buffer B the IgG-bound beads were resuspended in
500 µl TBS and transferred to a new tube. HEK293T cells were
collected in lysis buffer (20 mM tris, pH 7.5, 2.5mM DTT, 1%
Triton X-100, 300 mM NaCl)), sonicated and spun at 12,000 × g
for 10 min to remove debris and the supernatant was used for the
immunoprecipitations. The beads were incubated with 500 µg
total protein of HEK293T lysate with end over end mixing for
1 h at room temperature. Lysate samples prior to incubation
with the beads were reserved as the “Input” sample for western
blotting. After samples were incubated with beads, the unbound
sample was removed and saved for use as the “Post-IP” sample
for western blotting. The beads were washed 5x with 500 µl TBS
before transferring to a new tube. The final wash was removed
and beads were resuspended in 25 µl 2x Laemmli sample buffer.
SDS-PAGE and western blotting were done using 50 µg “Input”
and “Post-IP” samples, and 12.5 µl of each IP sample was used
for the “12B2-IP,” “15C2-IP” and “Ms IgG-IP” samples. The IP
experiments were repeated three independent times and western
blots (12B2, 15C2, and IgG control) were probed with rabbit
anti-GSK3 α/β total antibody (1:2,000, 5676, Cell Signaling) and
imaged as described below.
Western Blotting
Purified npS9 GSK3 antibodies were validated with recombinant
GSK3β and α protein and brain lysates from human, mouse
and rats (Kanaan et al., 2011, 2012). Recombinant protein
samples were prepared by using 300 ng GSK3β alone (His-tagged,
PV3365, Thermo, Waltham, MA, USA) or GSK3α alone (GST-
tagged, PV6126, Thermo, Waltham, MA, USA), GSK3β or α
incubated with alkaline phosphatase (6 U per reaction; EF0651,
Fermentas, Waltham, MA, USA) for 4 h at 30◦C to create a
non-phosphorylated GSK3 sample, and GSK3β or α incubated
with 2 µg Akt (14-276, Millipore, Billerica, MA, USA) and ATP
(400 µM) for 4 hrs at 30◦C to create a phosphorylated Ser GSK3
sample. The samples were brought to a final concentration of
8.33 ng/µl in 2x Laemmli sample buffer at 98◦ C for 10 min.
Human, mouse, and rat frontal cortex homogenates and cell
culture lysates (primary neurons were grown for 8 days at 45,000
cells/cm2 and cell lines were collected when∼80–90% confluent)
were prepared by sonicating samples in lysis buffer (20 mM
Tris, pH 7.5, 2.5 mM DTT, 300 mM NaCl, 1% Triton X-100).
Samples were centrifuged at 12,000 × g for 10 min at 4◦ C
and supernatants collected. Total protein concentrations were
determined using the Bradford protein assay (500-0006, BioRad,
Hercules, CA, USA).
Recombinant GSK3 samples were loaded at 50 ng/lane, while
the brain lysates and cell culture lysates were loaded at 50 µg/lane
and separated using SDS-PAGE on 4–20% Tris-HCl Criterion
gels (BioRad). Proteins were transferred onto PVDF membrane
(IPFL00010, Millipore, Billerica, MA, USA) and probed with
either 12B2 (1:1,000) or 15C2 (1:3,000) and total GSK3 α/β
(1:2,000; 5676, Cell Signaling), or with pS9 GSK3β (1:1,000; 9323,
Cell Signaling) and Ms total GSK3β (1:2,000 9832, Cell Signaling)
antibodies diluted in 5% non-fat dry milk in tris buffered saline
(TBS, 0.5 M Tris, 1.5 M sodium chloride, pH 7.4) overnight
at 4◦ C. Brain lysate blots were also probed with anti-GAPDH
antibody (1:2,000; 5174, Cell Signaling) for a loading control. The
following day the blots were incubated for 1 h at with IRDye
800CW goat anti-mouse IgG (H+ L) (1:20,000; 926-32210, LiCor
Biosciences, Lincoln, NE, USA) and IRDye 680LT goat anti-
rabbit IgG (H + L) (1:20,000; 926-68021, LiCor Biosciences)
for 12B2 and 15C2 antibody blots, or IRDye 680LT goat anti-
mouse IgG (H+ L) (1:20,000; 926-68020, LiCor Biosciences) and
IRDye 800CW goat anti-rabbit IgG (H+ L) (1:20,000; 925-32211,
LiCor Biosciences) for pS9 GSK3β blots. Immunoblots from the
Akt inhibitor and protein phosphatase inhibitor experiments (see
below) were probed with total Akt (1:2,000; 2920, Cell Signaling)
and either phospho-Thr308 Akt (1:1000; 13038, Cell Signaling)
or phospho-Ser473 Akt (1:2,000; 4060, Cell Signaling) antibodies,
and detected with IRDye 680LT goat anti-mouse IgG (H + L)
and IRDye 800CW goat anti-rabbit IgG (H + L) as above. Then
blots were imaged using a Licor Odyssey system. Band signal
intensities were quantified using ImageStudio software (v5.2.5,
LiCor Biosciences). The signals for 12B2, 15C2 and the pS9
GSK3β antibodies were normalized to total GSK3 signal in the
recombinant GSK3 blots.
Cell Culture Immunocytofluorescence
Primary neurons from E18 rat cortex, HEK293T and SH-SY5Y
cells were plated at 30,000 cells/well in 8-well chamber slides
coated with poly-D-lysine (to enhance cell adherence). Neurons
were grown for 8 days, while HEK293T and SH-SY5Y cells
were grown for 2 days before being fixed for 20 min at room
temperature using 4% paraformaldehyde in cytoskeletal buffer
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(10 mM MES, 138 mM KCl, 3 mM MgCl2, 4 mM EGTA, pH 6.1).
Fixed cells were rinsed 3x in TBS for 5 min each and then blocked
and permeabilized with 5% goat serum/1% BSA/0.2% Triton-X
for 1 hr at room temperature. Cells were stained with one of the
GSK3 primary antibodies diluted in 2% goat serum and incubated
overnight at 4◦ C (12B2 – 1:100; 15C2 – 1:100; total GSK3 α/β –
1:200). Cells were incubated in AlexaFluor goat anti-mouse IgG1
488 (A21121, Thermo) for 12B2 or 15C2 and AlexaFluor goat
anti-rabbit 568 (A11036, Thermo) for total GSK3 β/α (all diluted
1:500 in 2% goat serum). DAPI counterstain (0.5 µg/ml, D1306,
Thermo) was added to the first of four TBS rinses. Control stains
were performed where the primary antibodies were omitted to
confirm that each secondary label was specific to the appropriate
primary antibody (Supplementary Figure S3A). Image z-stacks
(0.5 µm step size) were taken using a Nikon A1+ laser scanning
confocal microscope system equipped with 488, 561, and 640
solid-state lasers, Nikon Elements AR software, and the images
(maximum intensity projections) were prepared for publication
using Adobe Photoshop and Illustrator.
Tissue Immunohistochemistry
Immunohistochemistry was performed on human control
(temporal lobe) and rat tissue sections (40 µm thick) following
established protocols (Kanaan et al., 2016). The tissue was
incubated with purified GSK3 antibodies (12B2 – 1:500 or
15C2 – 1:1,000) overnight at 4◦ C, followed by goat anti-
mouse biotinylated secondary antibody at 1:500 (115-065-
166, Jackson Immuno Research) and then ABC Elite solution
(according to the manufacturer’s instructions; PK-6100, Vector
Labs, Burlingame, CA, USA). The tissue was developed using
3,3′-diaminobenzidine (D5637, Sigma) at 0.5 mg/ml in TBS-
Tx with 0.003% H2O2 for 8 min. Control sections that were
stained following the same procedure, but without the primary
antibodies were performed (Supplementary Figure S3B). Images
were acquired as z-stacks (0.9 µm step size) with a Nikon Eclipse
90i microscope, a Nikon DS-Ri1 camera, and Nikon Elements AR
software (Nikon Instruments Inc., Melville, NY, USA), and the
images (displayed using the extended depth of focus function)
were prepared for publication using Adobe Photoshop and
Illustrator.
GSK3β Kinase Activity Assays
The GSK3β Kinase Enzyme System kit (V1991, Promega)
was used to generate a standard curve of GSK3β activity
per the manufacturer’s instructions. The active GSK3β enzyme
(G09-10G, lot P1578-8, Signal Chem) was brought to final
concentrations of 12, 9.6, 7.2, 4.8, and 2.4 ng/µl in 25 µl
reaction mixture containing 100 µM ATP (V915A, Promega) in
reaction buffer (40 mM Tris-HCl, pH 7.4, 20 mM MgCl2 and
0.1 mg/ml bovine serum albumin; supplied as a 5x stock). The
reactions were incubated at 30◦ C for 15 min. The reactions
were terminated and remaining ATP depleted by adding 25 µl
ADP-GloTM reagent (V912A, Promega) made according to
the manufacturer’s instructions. After 40 min incubation at
room temperature, 50 µl of the kinase detection reagent
(V913A and V914A, Promega, made according to manufacturer’s
instructions) was added to the reaction and incubated for 30 min
at room temperature. All samples were run in triplicate. Then
the luminescence was measured using a GloMax Muli-Detection
plate reader (E7031, Promega). The relative luminescence units
are directly proportional to the amount of ATP used during the
kinase reaction.
Nonphospho-S9 GSK3β Western Blotting
Curve
The 12B2 and 15C2 GSK3β antibodies were tested using
samples comprised of known amounts of npS9 GSK3β and
pS9 GSK3β. The npS9 GSK3β was obtained by incubating
GSK3β (1 µg, Thermo, PV3365) with alkaline phosphatase (15
U, Thermo, EF0654) for 5 h at 30◦ C. The pS9 GSK3β was
generated by incubating GSK3β (1 µg) with Akt1 (1 µg, P2999,
Thermo) and ATP (1 mM, N0440S, New England BioLabs)
in kinase buffer (20 mM Tris-HCl, pH 7.5, 10 mM MgCl2,
5 mM DTT) for 5 h at 30◦C. Akt1 is a kinase known to
phosphorylate S9 in GSK3β (Cross et al., 1994, 1995). The
following seven samples were generated that matched the levels
of npS9 GSK3β used in the kinase activity assay curve above: (1)
0% npS9 GSK3β (300 ng/lane pS9 GSK3β), (2) 10% npS9 GSK3β
(30 ng+ 270 ng/lane), (3) 20% npS9 GSK3β (60 ng+ 240 ng pS9
GSK3β), (4) 40% npS9 GSK3β (120 ng+ 180 ng pS9 GSK3β), (5)
60% npS9 GSK3β (180 ng + 120 ng pS9 GSK3β), (6) 80% npS9
GSK3β (240 ng + 60 ng pS9 GSK3β), and (7) 100% npS9 GSK3β
(300 ng+ 0 ng pS9 GSK3β). The samples were added to Laemmli
sample buffer, loaded at a total of 300 ng/lane, and separated on a
7.5% TGX precast Criterion gel for SDS-PAGE and subsequently
processed for western blotting using 12B2 or 15C2 antibody and
total GSK3β α/β as described above.
HEK293T Cell Culture Calyculin A
Treatment
HEK293T cells were grown for 48 hrs and then treated with
10 nM calyculin A (9902S, Cell Signaling Technology, Beverly,
MA, USA), a potent protein phosphatase inhibitor, for 30 min
to induce phosphorylation of S9 GSK3β prior to being collected
in lysis buffer (as above). Lysates were sonicated and centrifuged
at 12,000 × g for 10 min, the supernatants were collected the
Bradford Protein Assay was used to determine total protein
concentrations before being used in sandwich ELISA and GSK3β
activity assays.
The same lysates were used in a sandwich ELISA as described
previously (Kanaan et al., 2016). Briefly, all of these assays
were performed by coating wells in 96 well plates (Corning,
#3590) with 12B2 antibody (250 ng/well) as the capture antibody,
wells were blocked with 5% non-fat dried milk (1 h), then
incubated with the samples (see below), then incubated with
rabbit anti-total GSK3 α/β antibody (0.5 µg/ml, 1.5 h, same
antibody as above), and then incubated with goat anti-rabbit
antibody conjugated to horseradish peroxidase (Vector Labs, PI-
1000; (0.2 µg/ml; 1.5 h). Signal was detected with TMB for
25 min and then the reaction was stopped using 3.6% H2SO4.
The absorbance at 450 nm was measured and blank wells were
used to obtain background absorbance, which was removed from
sample signals. The following sandwich ELISAs sample sets were
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assayed. A recombinant npS9 GSK3β protein standard was run to
determine the amount of bound npS9 GSK3β in the experimental
lysate samples. Briefly, 2 µg of recombinant GSK3β (G09-10G,
Signal Chem) was incubated with 60 U alkaline phosphatase
(EF0651, Fermentas) at 30◦ C for 2 h to create the npS9 GSK3β
protein standard. Then 300-0.29 ng/well npS9 GSK3β was used to
create the standard curve (triplicate samples per concentration).
The absorbance values were log10 transformed and fit to a
sigmoidal curve (r2 = 0.999) and this was used to interpolate
the protein amounts in the experimental HEK cell lysate samples.
A HEK293T lysate standard curve also was run to establish that
the assay produces linear detection of npS9 GSK3β amounts from
lysate samples. The HEK293T lysate samples were applied at 7.5,
15, 30, 60, and 120µg. Finally, HEK293T lysates from control and
calyculin A treated cells were incubated in the sandwich ELISAs
(60 µg protein). For these experimental samples, the absorbance
values were used to interpolate unknown values of npS9 GSK3β
levels from the recombinant GSK3β standard curve assay (from
above) and the interpolated values were used for comparisons
between untreated control cells and calyculin A treated cells.
The same lysates were also used to measure GSK3β kinase
activity using an assay that combined the sandwich ELISA
approach with the GSK3β kinase activity assay described above.
Wells were coated with 12B2 (250 ng/well, diluted in borate
saline), blocked and then the samples were applied. Three
sample sets were tested, (1) a GSK3β enzyme standard (300 –
9.4 ng, diluted in TBS, G09-10G, Signal Chem), (2) control HEK
cell lysates and calyculin A (10 nM) treated HEK cell lysates,
and (3) both HEK cell lysates with a TCS-2002 (100 µM),
a GSK3β-specific inhibitor (Saitoh et al., 2009). The GSK3β
standard was used to ensure the experimental sample signals were
within the linear range of the assay. The control and calyculin A
treated lysates were used to confirm whether the changes in npS9
GSK3β levels seen in western blotting and sandwich ELISAs were
related to an actual reduction in GSK3β kinase activity. The TCS-
2002 inhibitor was used to confirm that the signals were derived
from GSK3β. After sample incubation, the wells were rinsed and
incubated in 50 µl/well GSK3β activity reaction buffer [100 µM
ATP (V915A, Promega), 40 mM Tris-HCl, pH 7.4, 20 mM MgCl2
and 0.1 mg/ml bovine serum albumin] for 1 h at 30◦C. Then,
the kinase reaction was stopped with 50 µl/well ADP-GloTM
reagent (V912A, Promega) made according to the manufacturer’s
instructions. After 40 min incubation at room temperature,
100 µl of the kinase detection reagent (V913A and V914A,
Promega, made according to manufacturer’s instructions) was
added to the reaction and incubated for 30 min at room
temperature. Then the luminescence was measured using a
GloMax Muli-Detection plate reader. The relative luminescence
units are directly proportional to the amount of ATP used during
the kinase reaction.
Akt Inhibitor and Protein Phosphatase
Treatments in HEK293T Cell Cultures
HEK293T cells were grown for 48 hrs and then treated with either
nothing (control), an Akt-specific inhibitor (AZD-5363, 1 µM,
15406, Cayman Chemical) (Davies et al., 2012; Li et al., 2013), a
protein phosphatase inhibitor (calyculin A, 10 nM, 9902S, Cell
Signaling Technology) or both AZD-5363 and calyculin A. In the
dual treatment cultures, cells were first treated with AZD-5363
for 1 h to inhibit the action of Akt on GSK3 (i.e., phosphorylation
at S9/21), and then calyculin A was applied for 30 min to
establish whether protein phosphatases dephosphorylate S9/21
independent of the Akt pathway (protein phosphatases can
increase Akt activity via causing accumulation of phospho-Akt or
they can directly dephosphorylate GSK3). Lysates were sonicated
and centrifuged at 12,000 × g for 10 min, the supernatants were
collected for western blotting analysis as above. The Bradford
Protein Assay was used to determine total protein concentrations.
Statistics and Data Analysis
All curve fitting and statistical analyses were performed using
Prism 6.0 (GraphPad Software, Inc.). The sandwich ELISA
data from the treatment of HEK293T cells with calyculin A
were compared using unpaired t-test. The western blotting
Akt inhibitor and protein phosphatase inhibitor experiment
data were compared using a one-way ANOVA, and post
hoc comparisons were made using the Holm-Sidak test.
Immunoblotting signal for 12B2 and 15C2 were correlated to
GSK3β enzyme activity using a Pearson’s r correlation analysis.
The GSK3β kinase activity assay data were compared using a two-
way ANOVA with calyculin treatment and TCS-2002 treatment
as the two factors, and post hoc comparisons were made using the
Holm-Sidak test. All tests were two-tailed and significance set at
p< 0.05.
RESULTS
Immunization with npS9 GKS3β Peptides
Mouse N00 was immunized with the N-terminal KLH npS9
GSK3β peptide and animals T10 and E10 were immunized with
a mixture of 3 peptides (N-term KLH, arginine enantiomer and
the tandem npS9 GSK3β peptides). All of the animals exhibited
strong titers against npS9 GSK3β and no detection of the pS9
GSK3β peptide (Supplementary Figures S1A,B). Animal T10
had the highest antibody titer after the third immunization
boost (A450 = 0.061 at 1:25,600; Supplementary Figure S1A)
and was used for the first fusion. Animal N00 had the highest
titer after the 6th immunization boost (A450 = 0.374 at 1:25,600;
Supplementary Figure S1B) and was used for a second fusion.
Hybridoma fusion cultures were screened for reactivity with
the npS9 GSK3β, pS9 GSK3β and npS21 GSK3α peptides to
determine their specificity prior to subcloning (Supplementary
Figures S1C,D). The 12B2 cultures showed stronger reactivity
for npS9 GSK3β over npS21 GSK3α, and did not react with pS9
GSK3β. The 15C2 culture showed slightly stronger reactivity with
npS21 GSK3α over npS9 GSK3β, and did not react with pS9
GSK3β. These cultures were subcloned three times, and with
each subcloning step the clones with the strongest reactivity
were continued forward (screened against the above peptides in
indirect ELISAs) and selected for production and purification.
Here, we characterized clone 12B2 (npS9 β-specific) and clone
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FIGURE 1 | 12B2 and 15C2 are specific for nonphospho-Ser GSK3β/α peptides. Each antibody was screened in indirect ELISA titers against npS9 GSK3β,
pS9 GSK3β, npS21 GSK3α and pS21 GSK3α peptides (n = 3 independent experiments). (A) 12B2 showed strong reactivity for npS9 GSK3β compared to npS21
GSK3α peptides and did not react with pS9 or pS21 GSK3 peptides (EC50 values: npS9 = 2.1 nM; pS9 = indeterminate (id); npS21 = 6.4 nM; pS21 = id). (B) To
further confirm the specificity of 12B2, ELISAs were performed by coating wells with a wide range of peptide amounts (0 – 6.4 µg peptide/well). 12B2 showed
strong reactivity with the npS GSK3 peptides (β > α), but did not react with pS GSK3 peptides. (C) 15C2 showed stronger reactivity for npS21 GSK3α compared to
npS9 GSK3β and did not react with pS9 or pS21 GSK3 peptides (EC50 values: npS9 = 2.4 nM; pS9 = id; npS21 = 277 pM; pS21 = id). (D) To further confirm the
specificity of 15C2, ELISAs were performed by coating wells with a wide range of peptide amounts (0 – 6.4 µg peptide/well). 15C2 showed strong reactivity with the
npS GSK3 peptides, but did not react with pS GSK peptides. It is noteworthy that synthetic peptides provide a homogeneous source of modified peptides, and
thus, are ideal for challenging the specificity of the antibodies against nonphospho-Ser and phospho-Ser residues in GSK3.
15C2 (npS β/α-specific), both of which produce IgG1 isotype
antibodies.
12B2 and 15C2 Antibody Specificity
Once purified, we titered the antibodies using npS9 GSK3β, pS9
GSK3β, npS21 GSK3α and pS21 GSK3α peptides in indirect
ELISAs. Clone 12B2 showed a higher affinity for npS9 GSK3β
(2.3 nM) compared to npS21 GSK3α (6.8 nM; Figure 1A).
Clone 15C2 had higher affinity for npS21 GSK3α (1.2 pM)
compared to npS9 GSK3β (10.6 nM; Figure 1C). Neither
of the antibodies reacted with pS9 GSK3β or pS21 GSK3α
peptides above background levels demonstrating their specificity
for npS GSK3 across a broad range of antibody dilutions
(starting as high as 67 nM or 1:100 dilution; Figures 1A,C).
Next, we further tested the limitations of 12B2 and 15C2
specificity across a broad range of peptide concentrations (0–
6.4 µg/well). There was strong reactivity with the npS peptides,
but again, no signals above background for the phospho-Ser
peptides confirming the specificity even at excessively high levels
of purified synthetic phospho-Ser peptides (i.e., 6.4 µg/well;
Figures 1B,D). It is noteworthy, that synthetic peptides provide
the most homogenous source of either phosphorylated or non-
phosphorylated antigens. To confirm that the synthetic pS9
GSK3β peptide contained a phosphorylated-Ser residue we also
performed an ELISA using the pS GSK3β-specific antibody, and
as expected, there was a strong signal demonstrating the peptide
contained phosphoS9 residues (Supplementary Figure S1E).
Three recombinant GSK3β (his-tagged) and GSK3α (GST-
tagged) protein samples were generated: (1) GSK3β or α alone, (2)
GSK3s incubated with alkaline phosphatase to dephosphorylate
S9 in GSK3β or S21 in GSK3α, or (3) GSK3s incubated with
Akt1 to phosphorylate S9 in GSK3β or S21 in GSK3α. These
samples were used to establish the specificity of the 12B2
and 15C2 with full-length GSK3 proteins. Blots were probed
with each antibody and a rabbit anti-total GSK3α/β antibody
(Figures 2A,B), or a rabbit anti-pS9 GSK3β antibody and a mouse
anti-total GSK3β antibody (Figure 2C). The 12B2 antibody
showed strong specificity for npS9 GSK3β and did not react with
pS9 GSK3β, npS21 GSKα or pS21 GSK3α proteins (Figure 2D).
The 15C2 antibody showed a weak preference for npS9 GSK3β
over npS21 GSK3α and did not react with pS9 GSK3β or pS21
GSK3α (Figure 2E). Phosphorylation of S9/S21 was confirmed
using the pS9 GSK3β antibody (Figure 2F).
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FIGURE 2 | 12B2 is specific for nonphospho-S9 recombinant GSK3β, and 15C2 is specific for nonphospho-S9/21 recombinant GSK3β/α. (A–C)
Western blots of recombinant GSK3β and α alone (input, In), phosphorylated S9 GSK3β and S21 GSK3α proteins (Ph; i.e., Akt1 treated) and dephosphorylated S9
GSK3β and S21 GSK3α proteins (NP; i.e., alkaline phosphatase treated). The GSK3α is GST-tagged and GSK3β is his-tagged, and in each blot the 12B2 (A), 15C2
(B) or pS9 GSK3β (C) antibodies are red, while total GSK3α/β antibody is green. (D) Quantitation of the 12B2 blots shows strong reactivity with npS9 GSK3β, and
none with npS21 GSK3α, pS9 GSK3β or pS21 GSK3α. (E) Quantitation of the 15C2 blots shows strong reactivity with npS9 GSK3β and npS21 GSK3α, but none
with pS9 GSK3β or pS21 GSK3α. (F) Quantitation of the pS9 GSK3 blots confirm that the Akt1 treatment produced robust phosphorylation of S9 in GSK3β (and
S21 in α) and that the alkaline phosphatase treatment removed phosphorylation of S9 in GSK3β (and S21 in α). Each experiment was repeated three-four
independent times and all samples were loaded at 50 ng GSK3/lane. The data are normalized to total GSK3 signal.
Next, we assessed the specificity and species cross reactivity
of 12B2 and 15C2 using human, mouse and rat brain lysates
since GSK3β is 100% conserved and there is a notable similarity
in GSK3α (Figure 3A). Total GSK3α/β antibody detected both
forms in humans, mice and rats (Figures 3B,C). The 12B2
antibody was specific for npS9 GSK3β and did not react
with npS21 GSK3α protein in human, mouse and rat lysates
(Figure 3B). In contrast, 15C2 detected both npS GSK3 isoforms
in human, mouse and rat lysates (Figure 3C). Cell lysates from
HEK293T (human), SH-SY5Y neuroblastoma cells (human),
U373 glioblastoma cells (human), primary neurons (rat), and
Neuro-2a neuroblastoma cells (mouse) were used to validate the
utility of 12B2 and 15C2 across multiple cell types. In all cell
types, 12B2 specifically labeled npS9 GSK3β (Supplementary
Figure S2A) and 15C2 labeled both npS21 GSK3α and npS9
GSK3β (Supplementary Figure S2B), but there were varying
degrees of each isoform in the different cell types. We also
used HEK293T cell lysates to establish the effectiveness of 12B2
and 15C2 in lysate immunoprecipitations. The 12B2 antibody
effectively immunoprecipitated GSK3β only (Figure 3D), while
the 15C2 antibody pulled down both GSK3α and β (Figure 3E).
The non-immune mouse IgG control did not immunoprecipitate
GSK3α or β (Figure 3F).
Based on the collective results from the assays above, 12B2
is a npS9 GSK3β-specific antibody and 15C2 is a npS9/21
GSK3β/α-specific antibody. Next, we further characterized
their reactivity in cell and tissue immunostaining procedures.
In general, immunofluorescence for 12B2 produced stronger
staining compared to 15C2 (Figure 4). The pattern of staining
produced by 12B2 was mostly punctate, and this was consistent
in HEK cells (Figure 4A), SH-SY5Y cells (Figure 4C) and E18
rat cortical neurons (Figure 4E). The 15C2 antibody produced
similar patterns of staining, but the overall signal was not
as robust as 12B2 in HEK cells (Figure 4B), SH-SY5Y cells
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FIGURE 3 | 12B2 and 15C2 are specific for nonphospho-S GSK3 in brain lysates of human, mouse, and rat, and both effectively immunoprecipitate
GSK3 from cell lysates. (A) Protein sequence alignments for GSK3β (amino acids 1–25) and GSK3α (amino acids 13–37) from human, mouse and rat (Uniprot IDs
in parentheses). (B,C) Blots of lysates from human, mouse and rat cortical tissue and GAPDH was used as a loading control (40 µg/lane total protein loaded;
experiment repeated three times). (B) 12B2 (red) specifically labeled GSK3β, not GSK3α, in lysates and total GSK3α/β (green) was used to identify both isoforms.
(C) 15C2 (red) labeled both GSK3β and GSK3α in lysates and total GSK3α/β (green) was used to identify both isoforms. (D–F) The 12B2 (D), 15C2 (E), or control
mouse IgG (F, Ms IgG) were used to immunoprecipitate GSK3 enzymes from HEK293T cell lysates. The starting lysate (Input) was incubated with magnetic beads
coated with 12B2 (D), 15C2 (E), or Ms IgG control (F) antibodies. 12B2 pulled down only GSK3β (12B2-IP), 15C2 pulled down both GSK3α and β (15C2-IP) and Ms
IgG did not pull down GSK3α or β (MsIgG-IP). The post-IP lysates were also run for comparisons to the input samples. These experiments were performed three
independent times.
(Figure 4D) and primary neurons (Figure 4F). Primary delete
stains confirmed that the pattern of staining was dependent upon
the 12B2 and 15C2 antibodies (Supplementary Figure S3A).
Brain tissue sections from rat and human brains were
processed for IHC. Both 12B2 (Figure 4G) and 15C2 (Figure 4H)
produced reactivity in the somata and processes of neurons, as
well as the parenchyma in the rat (retrosplenial cortex depicted)
and human brain (temporal lobe depicted). Primary delete
sections confirmed the signal was due to the primary antibodies,
and not non-specific reactivity from other components of the
staining procedure (Supplementary Figure S3B).
Finally, HEK293T cells were treated with siRNAs to further
confirm the specificity of 12B2 and 15C2 antibodies. Treatment
of cells with GSK3β siRNA reduced 12B2 signal (−50%) in
the GSK3β band, while GSK3α siRNA caused an increase in
12B2 signal (+35%) in the GSK3β band compared to control
(Figures 5A,B). Quantitation of total GSK3α/β antibody signal
showed that GSK3α siRNA reduced GSK3α levels (−66%)
and increased GSK3β (+29%), while GSK3β siRNA reduced
GSK3β (−41%) and increased GSK3α (+17%) when compared
to control cells (Figure 5C). The reduction in 12B2 signal
with GSK3β siRNA was apparent in the reduced signal with
immunocytochemistry (Figure 5D). Treatment of cells with
GSK3α siRNA reduced only the α band (−84%) detected
by 15C2, and treatment with GSK3β siRNA reduced only
the β band (−49%) detected by 15C2 compared to control
(Figures 6A,B). With GSK3α siRNA the GSK3β band detected
by 15C2 was increased (+22%), and with GSK3β siRNA the
GSK3α band detected by 15C2 was increased (+18%) compared
to control. Quantitation of total GSK3α/β antibody signal
showed that GSK3α siRNA reduced GSK3α levels (−66%)
and increased GSK3β (+24%), while GSK3β siRNA reduced
GSK3β (−40%) and increased GSK3α (+9%) when compared
to control cells (Figure 6C). The reduction in GSK3α and
GSK3β staining with 15C2 was apparent in the reduced signals
with immunocytochemistry (Figure 6D). The level of GAPDH
knockdown was −82% (Supplementary Figure S4A), and
GSK3α and GSK3β levels were reduced minimally by∼17% with
GAPDH siRNA treatment (Supplementary Figure S4B).
GSK3β Antibody Reactivity Correlates
with GSK3β Enzyme Activity
We used recombinant GSK3β proteins for our initial
demonstration that 12B2 and 15C2 reactivity reflects GSK3β
enzyme activity (Figures 7A–E). First, the level of GSK3β activity
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FIGURE 4 | GSK3β antibody immunostaining in cultured cells and tissue sections. (A,B) HEK293T cells stained with 12B2 (A, green) and 15C2 (B, green).
(C,D) Undifferentiated SH-SY5Y cells stained with 12B2 (C, green) and 15C2 (D, green). (E,F) Rat primary cortical neurons (E18) stained with 12B2 (E, green) and
15C2 (F, green). In A-F, all cells were also stained with total GSK3α/β (red) and DAPI (blue in merged image). The pattern of staining with 12B2 and 15C2 was
punctate staining throughout the cells, and 12B2 produced stronger signal than 15C2 in each cell type. Scale bars = 25 µm. (G,H) Brain sections in rat (left,
retrosplenial cortex displayed) and human (right, temporal cortex) stained with 12B2 (G) or 15C2 (H). In general, both antibodies produced clear somatodendritic
and parenchymal staining in human and rat brain sections. Scale bars = 50 µm.
was assessed using an in vitro GSK3β kinase activity assay that
uses luminescence to detect the amount of ADP (i.e., ATP
used) in a reaction mixture. The assay showed a positive linear
dose-response (r2 = 0.93, slope = 15727 ± 1080, p < 0.0001)
with increasing npS9 GSK3β (30 – 300 ng) (Figure 7A). Next,
we phosphorylated S9 by incubating GSK3β with Akt1 or
dephosphorylated S9 by incubating GSK3β with phosphatase
and then brought all samples to the same amount of total GSK3β
in each lane (300 ng total/lane containing 0, 10, 20, 40, 60, 80,
or 100% npS9 GSK3β). Blots probed with 12B2 (Figures 7B,C)
and 15C2 (Figures 7D,E) showed positive linear reactivity (12B2:
r2 = 0.92, slope = 0.0102 ± 0.0006, p < 0.0001; 15C2: r2 = 0.90,
slope = 0.001478 ± 0.0001, p < 0.0001) with increasing npS9
GSK3β. Notably, 12B2 and 15C2 did not show reactivity in the
0% npS9 GSK3β (containing 300 ng phospho-S9 GSK3β) samples
confirming the specificity for nonphospho-S9 GSK3 protein.
Finally, we correlated 12B2 or 15C2 blotting signal with GSK3β
kinase activity levels. Both 12B2 (r = 0.99, p = 0.0002) and 15C2
(r = 0.99; p < 0.0001) showed a strong positive correlation with
GSK3β activity assay as determined by the luminescence activity
assay.
Protein Phosphatase Inhibition
Decreases npS9 GSK3β Levels and
GSK3β Enzyme Activity in Cells
To provide a proof-of-principle demonstration of how these
new reagents can be used to gain biological insights we
focused on the 12B2 antibody because of its specificity
for the GSK3β isoform. We used 12B2 to examine the
regulation of GSK3β by protein phosphatases in cells. We
treated HEK cells for 30 min with 10 nM calyculin A, a
potent protein phosphatase inhibitor (Ishihara et al., 1989;
Resjo et al., 1999), which increases S9 phosphorylation in
GSK3β (Morfini et al., 2004; Kim et al., 2009; Xiao et al.,
2010). The cell lysates were analyzed in sandwich ELISAs,
GSK3β kinase activity assays, immunofluorescence, and western
blot.
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FIGURE 5 | siRNA knockdown of GSK3α and GSK3β demonstrate specificity of the 12B2 antibody. (A) HEK293T cells were treated with control, GSK3α,
GSK3β or GAPDH siRNAs and probed with 12B2 (red) and total GSK3β/α (green) antibodies. (B) Quantitation of 12B2 signal shows that GSK3β siRNA caused a
reduction of 50% for GSK3β when compared to control cells, while GSK3α siRNA caused an increase in GSK3β (+35%). (C) Quantitation of total GSK3α/β antibody
signal shows that GSK3α siRNA caused a loss of 66% for GSK3α and an increase in GSK3β (+29%) when compared to controls. Quantitation of total GSK3α/β
antibody signal shows that GSK3β siRNA caused a loss of 41% for GSK3β and an increase in the GSK3α (+17%) when compared to control cells. All
immunoblotting data are normalized to GAPDH signal and expressed as percent of the control group to illustrate the siRNA-mediated changes in signal.
(D) Immunocytofluorescence of HEK293T cells confirms the reduction in 12B2 detection of npS9 GSK3β, which produces a punctate staining pattern, in GSK3β
siRNA treated cells compared to control and GSK3α siRNA treated cells. Scale bars = 20 µm. Four independent experiments were performed. GAPDH siRNA
quantitation is provided in Supplementary Figure S4.
First, we used 12B2 sandwich ELISAs to quantitatively
measure the amount of npS9 GSK3β in these lysate samples.
A recombinant npS9 GSK3β standard curve (r2 = 0.999) was
used to interpolate the amount of npS9 GSK3β bound from the
lysates (Figure 8A). The 12B2 sandwich ELISAs were confirmed
to linearly detect npS9 GSK3β in HEK cell lysates by applying 120,
60, 30, 15, and 7.5 µg of total lysate protein, which produced a
linear response curve (r2 = 0.988) and 7.4, 5.2, 3.5, 2.0, and 0.9 ng
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FIGURE 6 | siRNA knockdown of GSK3α and GSK3β demonstrate specificity of the 15C2 antibody. (A) HEK293T cells were treated with control, GSK3α,
GSK3β or GAPDH siRNAs and probed with 15C2 (red) and total GSK3β/α (green) antibodies. (B) Quantitation of 15C2 signal shows that GSK3α siRNA caused a
loss of 84% for GSK3α and an increase in GSK3β (+22%) when compared to control cells. Quantitation of 15C2 shows that GSK3β siRNA caused a loss of 49% for
GSK3β and an increase in GSK3α (+18%) when compared to control. (C) Quantitation of total GSK3α/β antibody signal shows that GSK3α siRNA caused a loss of
66% in GSK3α and an increase in GSK3β (+24%) when compared to controls. Quantitation of total GSK3α/β antibody signal shows that GSK3β siRNA caused a
loss of 40% for the GSK3β and an increase in GSK3α (+9%) when compared to control cells. All immunoblotting data are normalized to GAPDH signal and
expressed as percent of the control group to illustrate the siRNA-mediated changes in signal. (D) Immunocytofluorescence of HEK293T cells confirms the reduction
in 15C2 detection of npS21 GSK3α or npS9 GSK3β when treated with GSK3α siRNA or GSK3β siRNA, respectively. Scale bars = 20 µm. Four independent
experiments were performed. GAPDH siRNA quantitation is provided in Supplementary Figure S4.
of npS9 GSK3β was detected (Figure 8B). The 12B2 sandwich
ELISAs were then used to quantitatively measure the amount
of npS9 GSK3β following calyculin A treatment. A significant
reduction in the amount of npS9 GSK3β [t(3) = 6.43, p = 0.008]
occurred after calyculin A treatment. Based on the recombinant
npS9 GSK3β standard curve the control samples contained
5.2 ± 0.12 ng and treated samples contained 4.0 ± 0.11 ng
npS9 GSK3β (per 60 µg total protein; Figure 8C). The reduction
in npS9 GSK3β levels was further confirmed by the qualitative
reduction of 12B2 reactivity in HEK293T cells treated with
calyculin A (Figure 8D).
To determine whether protein phosphatase treatment
caused reductions in GSK3β kinase activity, we ran the same
lysates in a kinase activity assay using 12B2 to capture GSK3β
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FIGURE 7 | Detection of recombinant npS9 GSK3β with 12B2 and 15C2 antibodies is linear and correlates with kinase activity. (A) The level of GSK3β
kinase activity with 30, 60, 120, 180, 240, and 300 ng of npS9 GSK3β (“active”) was measured using an in vitro GSK3β kinase activity assay and there was a linear
increase in kinase activity with increasing amounts of GSK3β (r2 = 0.93). Three independent experiments were performed. (B) For western blotting, recombinant
GSK3β was incubated with alkaline phosphatase to generate nonphosphoS9 GSK3β or incubated with Akt1 to generate phosphoS9 GSK3β, and then 0, 30, 60,
120, 180, 240, or 300 ng of npS9 GSK3β was mixed with 300, 240, 180, 120, 60, or 0 ng of pS9 GSK3β to bring the total protein content to 300 ng/lane. The blot
was probed with 12B2 (red) and total GSK3α/β antibodies (green). (C) Quantitation of signal from 12B2 shows a linear increase in reactivity with increasing npS9
GSK3β amount (r2 = 0.92). (D) The same samples were probed with 15C2 (red) and total GSK3α/β antibodies (green). (E) Quantitation of signal from 15C2 shows a
linear increase in reactivity with increasing npS9 GSK3β amount (r2 = 0.90). It is notable that both 12B2 and 15C2 signals also showed a direct correlation with
GSK3β activity levels (12B2: r = 0.99, p = 0.0002; 15C2: r = 0.99, p < 0.0001). Four independent experiments were performed.
from the samples. Serial dilution of recombinant GSK3β
enzyme produced a linear signal (r2 = 0.97; Figure 9A),
and all experimental lysate samples were within the linear
range. The activity of GSK3β was significantly reduced in
calyculin A treated cells compared to control cells [calyculin A
treatment factor: F(1,12) = 13.84, p = 0.003; TCS treatment
factor: F(1,12) = 156.5, p < 0.0001; interaction factor:
F(1,12) = 16.59, p = 0.002; Figure 9B]. Interpolation from
the recombinant GSK3β enzyme activity curve with known
amounts of GSK3β (Figure 9A) indicates that the control
samples contained 29 ng active GSK3β and the calyculin
A treated samples contained 15 ng active GSK3β (lysate
samples were used at 60 µg total protein/well). Treatment
with TCS-2002, the potent GSK3β inhibitor, completely
blocked kinase activity confirming GSK3β produced the signal
(Figure 9B).
Protein Phosphatases Dephosphorylate
S9/21 in GSK3β/α Independent of the Akt
Pathway
To further define the mechanisms of protein phosphatase-
mediated regulation of GSK3 we explored whether protein
phosphatases modify S9/21 independent of the Akt pathway
(Figure 10). Treatment of HEK293T cells with AZD-5363
(1 µM), an Akt inhibitor (Davies et al., 2012; Li et al., 2013),
caused a robust increase in npS9 GSK3β as detected with 12B2
[Figures 11A,B; F(3,12) = 69.97, p < 0.0001] and an increase in
both npS GSK3α and β as detected with 15C2 [Figures 11D–
F; F(3,12) = 67.17, p < 0.0001] when compared to controls. As
expected, this indicates that blocking Akt activity leads to the
accumulation of npS GSK3. Treatment of cells with calyculin
A (10 nM) caused a significant reduction in npS9 GSK3β as
detected with 12B2 (Figures 11A,B) and a reduction in both
npS GSK3α and β as detected with 15C2 (Figures 11D–F) when
compared to controls. This confirms that inhibiting phosphatase
activity allows phospho-S9/21 GSK3 to accumulate, but this can
occur through two pathways because phosphatases can directly
dephosphorylate both Akt (increasing phospho-Akt levels) and
GSK3 (decreasing nonphospho-GSK3 levels) (Figure 10). To
establish whether protein phosphatases dephosphorylate GSK3
at S9/21 independent of the Akt pathway, we first blocked Akt
activity with AZD-5363 (for 1 h) and then calyculin A was added
(for 30 min) to inhibit protein phosphatases. This treatment
paradigm produced a significant reduction in npS9 GSK3β as
indicated by 12B2 and both npS GSK3α and β as detected by
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 November 2016 | Volume 9 | Article 123
fnmol-09-00123 November 15, 2016 Time: 15:52 # 14
Grabinski and Kanaan Novel Nonphospho-Serine GSK3β/α Antibodies
FIGURE 8 | Treating cells with protein phosphatase inhibitor decreases npS9 GSK3β in cells. (A) A standard curve of dephosphorylated GSK3β protein
captured with 12B2 antibody was used for quantitative sandwich ELISAs (r2 = 0.999). (B) Untreated HEK293T lysates assayed in 12B2 sandwich ELISAs at 120,
60, 30, 15, and 7.5 µg total protein/well produces a linear dose response curve (r2 = 0.988). Interpolation using the standard curve in (A) indicates that the lysate
samples contain 7.4, 5.2, 3.5, 2.0, and 0.9 ng of npS9 GSK3β, respectively. (C) HEK293T cells were either untreated (-) or treated with 10 nM calyculin A for 30 min
(+) to reduce npS9 GSK3β levels (n = 4 independent experiments). The lysates were used in 12B2 sandwich ELISAs. A significant reduction in npS9 GSK3β levels
was detected in calyculin A (10 nM) treated cells compared to untreated cells (∗p < 0.05, unpaired t-test, two-tailed). The amount of npS9 GSK3β was quantitatively
determined by interpolation using the recombinant GSK3β standard curve in (A). (D) Immunofluorescence for 12B2 (green) showed an apparent qualitative reduction
in npS9 GSK3β levels in HEK cells treated with calyculin A when compared to control cells. Cells were also stained with total GSK3α/β (red) and DAPI. Scale
bar = 25 µm.
15C2 (Figures 11D–F) when compared to AZD-5363 alone.
Furthermore, we observed the opposite result when blots were
probed with a pS9 GSK3β antibody [Figure 11C, F(3,12) = 46.79,
p< 0.0001]. The AZD-5363 alone treatment resulted in increased
active Akt levels [i.e., pT308 and pS473 Akt; Supplementary
Figures S5A–C, pT308: F(3,12) = 20.13, p < 0.0001; pS473:
F(3,12) = 7.699, p = 0.004] and increased npS GSK3 levels
demonstrating that we effectively blocked Akt activity at the
dose used (ineffective inhibition would lead to reduced npS
GSK3 and increased pS GSK3 in the presence of elevated
active Akt levels). It is noteworthy that neither total GSK3α/β
[Total α: F(3,12) = 1.824, p = 0.20; Total β: F(3,12) = 0.926,
p = 0.46] nor total Akt levels [F(3,12) = 0.955, p = 0.45]
were significantly affected with these treatments (Supplementary
Figures S5D,E).
DISCUSSION
The GSK3β enzyme is one of the most widely studied S/T
kinases because of its role in several biological processes (Kim
and Kimmel, 2006; Kockeritz et al., 2006; Forde and Dale, 2007;
Hur and Zhou, 2010; Medina and Wandosell, 2011; Beurel
et al., 2015) and disease states (Hernandez and Avila, 2008;
Cadigan and Peifer, 2009; Golpich et al., 2015; Lal et al., 2015; Li
et al., 2015; O’Leary and Nolan, 2015). Not surprisingly, GSK3β
regulation is tightly controlled by several mechanisms including
phosphorylation, substrate priming, truncation, protein complex
association and subcellular localization (Medina and Wandosell,
2011). Phosphorylation is the most prominent and well-
understood regulatory mechanisms, and phosphorylation of
S9 in GSK3β (S21 in GSK3α) is a dominant negative
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FIGURE 9 | Protein phosphatase inhibition significantly reduces GSK3β kinase activity in cells. (A) A standard curve of active GSK3β enzyme (300 –
9.4 ng) confirmed the signal in the experimental samples was within the linear range of detection in this assay (r2 = 0.97). Experiment was repeated three times.
(B) Calyculin A treated cells showed a significant reduction in GSK3β kinase activity compared to control cells (the –TCS sample sets; all samples were used at
60 µg total protein/well). Interpolation from the recombinant GSK3β enzyme activity curve with known amounts of active GSK3β indicated that the control samples
contained 29 ng of active GSK3β and calyculin A treated cells contained 15 ng. Addition of TCS-2002 (0.1 mM; +TCS), a potent GSK3β inhibitor, completely
blocked kinase activity in control and calyculin A treated cells (∗p < 0.05, two-way ANOVA with Holm-Sidak post hoc test, two-tailed). Note that the same lysate
samples used here were used in Figure 8. This experiment was repeated four times.
FIGURE 10 | The Akt-protein phosphatase signaling pathway involved in regulating GSK3β phosphorylation. Active Akt (i.e., phosphorylated) inactivates
GSK3β by phosphorylation at S9. Protein phosphatases can modulate GSK3β phosphorylation at S9 via two routes. (1) Protein phosphatases inactivate Akt by
dephosphorylation, and (2) protein phosphatases activate GSK3β by directly dephosphorylating S9. Inhibition of Akt (with inhibitors such as AZD-5363) increases
non-phosphorylated GSK3β by suppressing Akt-mediated phosphorylation of GSK3β. Inhibition of protein phosphatases (with inhibitors such as calyculin A) causes
a decrease in non-phosphorylated GSK3β through the Akt pathway by increasing active Akt (the grayed portion of the Akt cycle). Protein phosphatase inhibition also
leads to decreased non-phosphorylated GSK3β independent of Akt by directly dephosphorylating S9 in GSK3β. If an Akt inhibitor is applied followed by a protein
phosphatase inhibitor the Akt-independent pathway can be evaluated.
regulatory mechanism because the pS9 region competitively
blocks substrate docking by mimicking primed substrates.
In general, when S9 is not phosphorylated, the enzyme
is typically considered “active” because other modifications
such as phosphorylation of tyrosine 216 (or tyrosine 276
in GSK3α) appear to occur at near stoichiometric levels
and during translation in a chaperone-dependent mechanism
(Hughes et al., 1993; Wang et al., 1994a; Cohen and Goedert,
2004; Cole et al., 2004). However, there are other Ser/Thr
residues in GSK3β, such as T43, T390 and S389, that are
targets of other kinases (i.e., Erk and/or p38 MAPK) and
modulate the activity of GSK3β as well (Ding et al., 2005;
Thornton et al., 2008). Thus, levels of npS9 GSK3β can
generally be a useful surrogate marker for the amount of
GSK3 in an “active-state,” and here we show that 12B2 or
15C2 reactivity in western blots correlates well with kinase
activity (at least using recombinant proteins in vitro). However,
the npS GSK3 antibodies do not directly speak to kinase
activity levels and GSK3β activity should be directly assayed
when possible. To this end, we demonstrate that 12B2
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FIGURE 11 | Protein phosphatases regulate GSK3β phosphorylation independent of Akt signaling. HEK293T cells were treated with an Akt inhibitor
(AZD-5363, 1 µM), a protein phosphatase inhibitor (calyculin A, 10 nM) or the Akt inhibitor followed by the phosphatase inhibitor. Four independent experiments
were run. (A) Western blots of samples were probed with 12B2 (npS9-GSK3β specific), total GSK3α/β, pS9-GSK3β and GAPDH (loading control). (B) Quantitation
of the blots shows that inhibition of Akt (AZD) significantly increased npS9 GSK3β, while inhibition of protein phosphatases (Caly) significantly reduced npS9 GSK3β.
When Akt signaling was blocked first and then the phosphatase inhibitor was applied (AZD + Caly) a significant reduction in the level of npS9 GSK3β occurred when
compared to Akt inhibitor alone. (C) Quantitation of the pS9 GSK3β blots shows an opposite pattern where inhibition of Akt significantly decreased pS9 GSK3β,
while inhibition of phosphatases significantly increased pS9 GSK3β. When Akt signaling was blocked and then the phosphatase inhibitor was applied a significant
increase in the level of pS9 GSK3β occurred when compared to Akt treatment alone. (D) Western blots of samples were probed with 15C2 (npS9-GSK3α/β specific),
total GSK3α/β, pS9-GSK3β and GAPDH (loading control). (E,F) Quantitation of the blots shows that inhibition of Akt significantly increased npS9 GSK3α and β, while
inhibition of protein phosphatases significantly reduced npS9 GSK3α and β. When Akt signaling was blocked and then the phosphatase inhibitor was applied a
significant reduction in the level of npS9 GSK3β and npS21 GSK3α occurred when compared to Akt inhibitor alone. Collectively, these results suggest protein
phosphatases dephosphorylate Ser9/21 independent of Akt signaling. All bands are normalized to GAPDH. All groups were statistically significant from the others in
(B,C,E,F), but only ∗p < 0.05 vs. control and ∗∗p < 0.05 vs. AZD alone are indicated to simplify the graph and highlight the critical comparisons (one-way ANOVA,
Holm-Sidak post hoc test). Total GSK3α/β levels, total Akt and phospho-Akt immunoblots from these experiment are displayed in Supplementary Figure S5.
can be applied in assays that allow direct measurement of
GSK3β kinase activity in experimental lysates, and that the
same reagent directly measures npS9 GSK3β in several assay
formats.
Considerations for Producing Stable,
High-Quality Monoclonal Antibodies
Our understanding is that npS9 GSK3β reagents were difficult
to obtain by other groups and companies. We used a relatively
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unique immunization approach by combining a normal peptide,
a tandem repeat peptide and an arginine enantiomer peptide. The
tandem peptide provides more antigens specifically centered on
the residue of interest, while arginine enantiomers are known
to enhance antigenicity (Benkirane et al., 1993; Guichard et al.,
1994). We rule out antibodies that react against KLH, neoepitopes
in the tandem peptide and the D-arginine by using normal
GSK3β peptides not conjugated to KLH in all screening assays.
Moreover, we place a great deal of importance on identifying
specificity early in the process. For example, assessing differences
in reactivity for npS9 GSK3β, pS9 GSK3β and npS21 GSK3α
begins at the fusion stage. We also require relatively robust serum
titer signal (1:25,000 or greater dilution), high levels of reactivity
in subsequent ELISAs (absorbance >1.0), stability after repeated
freeze/thaw cycles, and mycoplasma negativity to consider a line
stable and of sufficient quality. Typically, we subclone lines 2–3
times every time we retrieve a clone from long-term storage to
ensure clone stability and consistency. Overall, these criteria help
establish high quality, sustainable lines for producing reagents
indefinitely.
Advantages of the New GSK3 Antibody
Reagents
Despite the importance of GSK3 and widespread interest in
GSK3, reagents for directly measuring npS9/21 GSK3β/α (i.e.,
the so-called “active” form) did not exist. Currently available
antibodies allow only indirect assessment of changes in GSK3
activation by looking at the phosphorylated N-terminal serine
residues and many of them lack a high degree of specificity.
We provide rigorous, detailed characterization of two novel
monoclonal antibodies. The 12B2 antibody specifically detects
npS9 GSK3β, and lacks reactivity when S9 is phosphorylated
and does not react with GSK3α proteins. The 15C2 antibody
works similarly with GSK3β but also detects npS21 GSK3α
making it useful for also studying GSK3α regulation. It is
noteworthy that neither of these antibodies showed detectable
reactivity against phospho-S9/21 peptides in ELISAs (even when
high antibody concentrations or large amounts of peptides were
used) or against in vitro phosphorylated recombinant GSK3 in
western blotting (up to 300 ng protein). Evaluating total GSK3β
levels is not required with these new reagents when equivalent
samples are used, but this may remain a valuable assessment
if determining whether experimental conditions alter both the
amount of npS9 GSK3β and total GSK3β is desired. All of the
reagents detect GSK3 enzymes in human, mouse and rat, as
well a number of commonly used human, mouse and rat cell
types, which is expected considering the high homology across
these species. The high sequence homology in this region goes
across many species (both vertebrates and invertebrates) (Forde
and Dale, 2007), which likely expands the usefulness of these
reagents.
The fact that these antibodies work in several assays further
highlights their advantages. We tested these antibodies in
indirect ELISAs, western blotting, immunoprecipitations, cell
culture ICF, and tissue section IHC using a range of samples
including synthetic peptides, recombinant GSK3β and α, as
well as human and rodent cells and tissues. Providing npS9
GSK3-specific reagents will allow researchers versatility and
the added benefit of using the same reagents in several
assay formats. The fact that these antibodies work in both
biochemical assays and immunostaining assays in cultured
cells and tissue sections represents another advantage because
identifying subcellular localization of changes in npS9 GSK3β
can be directly related to changes in protein levels and
kinase activity. Interestingly, the immunofluorescence studies
in cultured cells showed a predominance of punctate staining
with npS9 GSK3β antibodies (particularly 12B2), which may
represent signalosomes or other multi-component complexes
containing npS9 GSK3β enzymes (Bilic et al., 2007; Cadigan
and Peifer, 2009). In fact, the siRNA studies clearly show that
these puncta are reduced in cells, confirming they contain
npS9 GSK3β. Thus, the reagents described here provide
new all-in-one reagents for directly measuring npS9 GSK3β
and GSK3β kinase activity levels that exhibit great assay
versatility, subcellular localization and cross-species utilization
(Table 1).
The most compelling data supporting the use of these
antibodies to provide biological insights are those confirming
that they directly measure, in a linear fashion, the amount
of npS9 GSK3β. We demonstrate that these reagents detect
changes in the amount of npS9 GSK3β and that the signals
on immunoblots correlate very well with the kinase activity
of GSK3β using recombinant proteins and experimentally
induced GSK3β inhibition (e.g., calyculin treated cells).
Moreover, the use of a recombinant protein standard curve
in the sandwich ELISAs and the kinase activity assays
allows quantitation of unknown amounts of active GSK3β
TABLE 1 | Summary of GSK3β antibody performance in assays tested in the current work.
Antibody
(Isotype)
Peptide
Indirect
ELISA
Rec Prot
WB
Brain
Lysate WB
Lysate
IP
Rec Prot
sELISA
Lysate
sELISA
IHC (rat
brain)
IHC
(human
brain)
ICF
(culture)
WB
(activity
assay
samples)
Kinase
Activity
Assay
12B2
(IgG1)
β > > α β only β only Yes (β) ++ Yes
r2 = 0.99
+++ +++ ++ r2 = 0.92
p < 0.0001
Yes
15C2
(IgG1)
β < α β < α β < α Yes (α/β) – nd +++ +++ ++ r2 = 0.90
p < 0.0001
nd
– poor or no signal, + weak signal, ++ moderate signal, +++ strong signal and ++++ best signal relative to other antibodies. Rec Prot, recombinant protein; ELISA,
enzyme linked immunosorbent assay; WB, western blot; IP, immunoprecipitation; sELISA, sandwich ELISA; IP, immunoprecipitation; IHC, immunohistochemistry; ICF,
immunocytofluorescence; nd, not determined.
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and GSK3β activity levels in whole cell lysates. A few
approaches are currently used to measure GSK3β activity
in experimental lysate samples that often involve combining
immunoprecipitation of total GSK3β and in vitro GSK3β
activity assays (Welsh et al., 1997; Bijur and Jope, 2001;
Bowley et al., 2005). Thus, these reagents have a distinct
advantage over currently available reagents because other
reagents do no target the npS9 (or “active”) form of GSK3β, and
subsequently the new antibodies enhance our ability to study
GSK3 regulation.
The performance of each antibody was remarkably similar
across assays, but some differences were observed. For instance,
the synthetic peptide indirect ELISAs showed moderate affinity
differences between GSK3β and GSK3α with 12B2, while 15C2
showed a stronger reaction with GSK3α over GSK3β peptides.
However, assays that used the full-length protein showed the
differential affinity for GSK3β and α was substantial for 12B2,
and 15C2 reacted equally as well with both forms of GSK3.
Once lysate samples were used, the differential reactivity between
GSK3β and GSK3α were quite robust with no 12B2 reactivity for
GSK3α under the conditions used. Overall, 12B2 produced results
demonstrating it is specific to npS9 GSK3β isoform, while 15C2
is specific to npS9 GSK3β and npS21 GSK3α.
Novel GSK3β Antibodies Demonstrate
that Protein Phosphatases Reduce npS9
GSK3β Levels and Kinase Activity
through an Akt-Independent Pathway
Protein phosphatases are thought to regulate GSK3β activity
through dephosphorylation of S9, where increased phosphatase
activity leads to increased GSK3β activity, and likewise, protein
phosphatase inhibition causes GSK3β inhibition by reducing
nonphospho-S9 GSK3β. Indeed, this regulatory pathway appears
to play a role in GSK3β activation under several biological
contexts, including cell excitability, survival of leukemic
progenitors, insulin signaling, growth factor signaling, and
motor protein regulation, among others (Sutherland et al., 1993;
Leung-Hagesteijn et al., 2001; Morfini et al., 2004; Lee et al.,
2005; Szatmari et al., 2005; Bertrand et al., 2012; Ma et al.,
2012). However, protein phosphatases also may influence GSK3β
phosphorylation through the Akt pathway (Millward et al.,
1999; Bononi et al., 2011). In the Akt pathway, stimulation of the
phosphoinositide 3-kinase/Akt pathway leads to activation of Akt
via phosphorylation of T308 and S473 residues, and then active
Akt phosphorylates GSK3β/α at S9/21 (Gold et al., 2000; Varea
et al., 2010; Majewska and Szeliga, 2016). Protein phosphatases
(in particular protein phosphatase 2A) dephosphorylate Akt
leading to Akt inactivation, and subsequently increased active
GSK3β/α via the loss of Akt-mediated S9/21 phosphorylation
(Millward et al., 1999; Bononi et al., 2011).
Previous studies were unable to directly demonstrate
that protein phosphatases-mediated effects were due to
changes in the npS9 GSK3β because such reagents did not
exist. Furthermore, we set out to determine whether protein
phosphatases dephosphorylate GSK3β/α at S9/S21 independent
of Akt signaling. Our results using both 12B2 and 15C2 suggest
that protein phosphatases decrease npS9/21 GSK3β/α levels via
direct dephosphorylation that is independent of the Akt pathway.
As expected, blocking Akt activity robustly increased levels of npS
GSK3 because Akt could no longer phosphorylate GSK3, despite
an elevation in active Akt levels (i.e., pT308 and pS473 Akt).
When Akt was inhibited to eliminate contributions of the Akt
pathway prior to application of protein phosphatase inhibitor,
there was a significant reduction in npS GSK3 and increase in
pS GSK3 suggesting that GSK3 dephosphorylation by protein
phosphatases occurs independent of Akt pathway. We also show
that the reduced levels of npS9 GSK3β in HEK293 cells treated
with protein phosphatase inhibitor causes a reduction in GSK3β
kinase activity by using the 12B2 npS9 GSK3β antibody. In fact,
the same reagent was used to validate this biologically relevant
mechanism of GSK3β regulation across several assay formats,
including western blots, ELISAs, immunocytofluorescence
and kinase activity assays. Thus, these reagents show strong
inter-assay validation and should provide researchers the ability
to directly and more accurately study GSK3β regulation and
activity across many biological contexts.
CONCLUSION
The lack of reagents that specifically and directly assess the level
of npS9/21 GSK3β/α has burdened the research community.
Here, we provide the characterization of one monoclonal
antibody that specifically reacts with GSK3β when S9 is not
phosphorylated, as well as one antibody that also reacts with
GSK3α when S21 is not phosphorylated. Notably, these reagents
will allow researchers to directly measure the level of npS GSK3
in experimental conditions using a wide range of assay formats.
We provide evidence that these reagents will help researchers
study GSK3β regulation in biological systems by demonstrating
that protein phosphatase inhibition leads to reduced GSK3β
activity via reductions in amount of npS9 forms of GSK3β
independent of Akt signaling. Collectively, these reagents should
provide significant advantages over existing reagents and will
help to facilitate GSK3β research across many fields of biology.
Finally, if changes in GSK3β activity are an important marker
for a particular disease state, which is likely considering the
involvement of GSK3β in several disease processes, these
reagents may be extremely useful in developing diagnostic and/or
biomarker assays for diseases.
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FIGURE S1 | Hybridoma fusion and subcloning procedures. (A–C) Indirect
ELISA titer of serum from immunized animals after the 3rd (A) and 6th (B)
immunization boost. Animal T10 and N00 were used for fusions because they
produced the strongest reactivity after the 3rd and 6th boosts, respectively. (C,D)
The fusion cultures were screened against npS9 GSK3β, pS9 GSK3β and npS21
GSK3α peptides. ∗ indicates reactivity with npS9 much greater than npS21 GSK3α
and no reactivity with pS9 GSK3β; ∗∗ indicates reactivity with more npS21 GSK3α
than npS9 GSK3β and no reactivity with pS9 GSK3β. The 12B2 (C) and15C2 (D)
cultures were continued to the first subclone. Subsequent subclone cultures were
similarly screened against these peptides in indirect ELISAs (using same method)
to evaluate specificity during the cloning process (data not shown). We typically
require that the percent of reactive clone wells should be ≥95% by the third
subclone (12B2 = 99% and 15C2 = 100%). (E) Phosphorylation at serine 9 of the
pS9 GSK3β peptide was confirmed using a pS9 GSK3β-specific antibody in
indirect ELISAs.
FIGURE S2 | 12B2 and 15C2 label npS GSK3 isoforms in multiple cell
types. (A) Cell lysates from SH-SY5Y neuroblastoma cells (human), HEK293T
cells (human), primary neurons (rat), U373 glioblastoma cells (human), and
Neuro-2a neuroblastoma cells (mouse, N2a) were probed with total GSK3α/β
(green) and 12B2 (red) antibodies to detect npS9 GSK3β. Much like the brain
lysates in Figure 3, 12B2 specifically labels only npS9 GSK3β in all cell types, but
varying amounts were detected in the difference cells (all loaded at 50 µg/lane).
(B) Cell lysates from the same cells were probed with total GSK3α/β (green) and
15C2 (red) antibodies to detect npS9/21 GSK3β/α. Much like the brain lysates in
Figure 3, 15C2 specifically labels both npS9 GSK3β and npS21 GSK3α in all cell
types, but varying amounts were detected in the difference cells (all loaded at
50 µg/lane).
FIGURE S3 | Primary delete controls for cell culture immunofluorescence
and tissue immunohistochemistry. (A) HEK293T cells were processed for
immunofluorescence with the exception that the npS9 GSK3β (green channel) and
total GSK3 α/β (red channel) primary antibodies were omitted (cells were
counterstained with DAPI, blue channel). A lack of staining confirms that the
signals were due to reactivity with the primary antibodies and not artifacts from
other components of the staining procedure or imaging cells with fluorescence.
(B) Rat and human tissue sections were processed for immunohistochemistry
with the exception that the npS9 GSK3β antibodies were omitted. A lack of
staining confirms that the signals were due to reactivity with the primary antibody
and not artifacts from processing tissue through the staining procedure. All scale
bars in (A,B) are 50 µm.
FIGURE S4 | Effects of GAPDH siRNA in HEK293T Cells. HEK293T cells were
treated with GAPDH siRNAs and probed with 12B2 or 15C2 and total GSK3β/α
antibodies (see Figures 5A and 6A for blot images). (A) Quantification shows that
GSK3β siRNA caused a reduction of 82% in signal for the GAPDH when
compared to control cells. (B) Quantification of the GSK3α and GSK3β bands with
15C2 (which labels both npS9 GSK3β and npS21 GSK3α) showed only minimal
changes compared to controls (−17%).
FIGURE S5 | Akt inhibitor and protein phosphatase inhibitor treatments
affect Akt phosphorylation, but not total Akt or GSK3 levels. HEK293T cells
were treated with an Akt inhibitor (AZD-5363, 1 µM), a protein phosphatase
inhibitor (calyculin A, 10 nM) or the Akt inhibitor followed by the phosphatase
inhibitor to demonstrate the potential utility of 12B2 and 15C2 in studying GSK3
regulation. Four independent experiments were run (same as Figure 11). (A)
Western blots of samples were probed with pT308 Akt and pS473 Akt (active
phospho-Akt), total Akt and GAPDH (loading control). (B,C) Quantitation of the
blots shows that inhibition of Akt (AZD) significantly increased both (B) pT308 and
(C) pS473 Akt. The fact that AZD caused upregulation of npS9/21 GSK3β/α (see
Figure 11) and increased active phospho-Akt (which would normally decrease
npS GSK3 levels) confirms the effectiveness of the AZD dose. (D,E) None of the
treatments significantly affected the levels of (D) total Akt (p = 0.45), as well as (E)
total GSKα (p = 0.20) or total GSK3β (p = 0.46). All bands are normalized to
GAPDH. (∗p < 0.05 vs. control; one-way ANOVA, Holm-Sidak post hoc test).
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